Intradigm is Biotechnology in United States that focus on RNAi therapeutics platform business. Founded in 2000. They cover business area such as developer, systematic ribonucleic acid interference, RNAi) therapeutic, serious disease, an initial focus, oncology, RNAi molecule, biodegradable polycationic polymer, rnai therapeutic, sirna sequence application, a portfolio, siRNA sequence.
2000
( 26 years old in 2026 )
RNAi Therapeutics Platform
-
3350 West Bayshore Road
Suite 100
Palo Alto, CA 94303
United States
Private
developersystematic ribonucleic acid interferenceRNAi) therapeuticserious diseasean initial focusoncologyRNAi moleculebiodegradable polycationic polymerrnai therapeuticsirna sequence applicationa portfoliosiRNA sequence
* We use standard office opening hours in near Intradigm's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Intradigm is Biotechnology business from United States that founded in 2000 (26 years old in 2026), Intradigm business is focusing on RNAi Therapeutics Platform.
Intradigm headquarter office and corporate office address is located in 3350 West Bayshore Road Suite 100 Palo Alto, CA 94303 United States.
Intradigm was founded in United States.
In 2026, Intradigm is currently focus on RNAi therapeutics platform sector.
Above is snippet of Google Trends for "RNAi therapeutics platform" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Intradigm, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
